{"atc_code":"N06AX22","metadata":{"last_updated":"2021-01-28T03:12:22.081801Z","applied_components":{"EmaDataAccessor":{"output_fields":[],"input_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","last_success":"2021-01-28T03:12:22.081793Z","output_checksum":"44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a","success":true,"name":"EmaDataAccessor","input_fields":[],"version":3,"finish_time":"2021-01-28T03:12:22.081793Z","status":"UP_TO_DATE"},"historic_pivotal_studies":{"output_fields":["attachment.studies.known_pivotal"],"input_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","last_success":"2021-01-28T11:00:16.754610Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"historic_pivotal_studies","input_fields":["attachment.studies.study_ids"],"version":2,"finish_time":"2021-01-28T11:00:16.754610Z","status":"UP_TO_DATE"},"section_ranges_extraction":{"output_fields":["attachment.labelSections"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-01-28T17:04:25.405344Z","output_checksum":"f429f64808d84b4b08098bf403595a8de2439affb9624c54bcfd025793addffd","success":true,"name":"section_ranges_extraction","input_fields":["attachment.type","attachment.content"],"version":2,"finish_time":"2021-01-28T17:04:25.405344Z","status":"UP_TO_DATE"},"prime_designation_enricher":{"output_fields":["prime_designation"],"input_checksum":"f336b21f17bdbcfc74c5f49abbcce54162c9017178a5ee9ba10e465e20f90ce9","last_success":"2021-01-28T23:53:22.336738Z","output_checksum":"dcf4d2ed94fa29974e643bd4a70cd26ec785f1130958f3e23e8022193699a97a","success":true,"name":"prime_designation_enricher","input_fields":["attachment.type","attachment.content"],"version":3,"finish_time":"2021-01-28T23:53:22.336738Z","status":"UP_TO_DATE"}},"agency":"EMA","product_id":"AD652F8A281AE09AABAF0580FFB1EA54","direct_link":"https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan","first_created":"2021-01-28T03:12:21.906637Z"},"revision_number":22,"approval_status":"authorised","active_substance":"Agomelatine","additional_monitoring":false,"inn":"Agomelatine","prime_designation":false,"accelerated_assessment":false,"orphan":false,"product_name":"Valdoxan","authorization_holder":"Les Laboratoires Servier","generic":false,"product_number":"EMEA/H/C/000915","initial_approval_date":"2009-02-19","attachment":[{"last_updated":"2020-07-03","link":"https://www.ema.europa.eu/documents/product-information/valdoxan-epar-product-information_en.pdf","id":"D10B481F019ABBC8E31F31355AA452A0","type":"productinformation","title":"Valdoxan : EPAR - Product Information","first_published":"2009-03-17"}],"conditional_approval":false,"exceptional_circumstances":false,"indication":"<div> \n <div class=\"ecl-field__body\"> \n  <div class=\"ecl-editor first last\">\n   <p>Treatment of major depressive episodes in adults.</p>\n  </div> \n </div> \n</div>","therapeutic_area":"Depressive Disorder, Major","contact_address":"50, rue Carnot\nF-92284 Suresnes Cedex\nFrance","biosimilar":false}